Exchange Traded Concepts LLC Sells 13,839 Shares of Protagonist Therapeutics, Inc. $PTGX

Exchange Traded Concepts LLC reduced its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 29.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,552 shares of the company’s stock after selling 13,839 shares during the period. Exchange Traded Concepts LLC owned about 0.05% of Protagonist Therapeutics worth $2,229,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in PTGX. Commodore Capital LP acquired a new stake in Protagonist Therapeutics during the 2nd quarter worth approximately $59,415,000. Adage Capital Partners GP L.L.C. increased its position in Protagonist Therapeutics by 218.0% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,092,262 shares of the company’s stock valued at $60,369,000 after acquiring an additional 748,758 shares during the period. BVF Inc. IL raised its stake in shares of Protagonist Therapeutics by 35.5% during the first quarter. BVF Inc. IL now owns 2,575,015 shares of the company’s stock valued at $124,528,000 after acquiring an additional 675,000 shares during the last quarter. Holocene Advisors LP acquired a new position in shares of Protagonist Therapeutics during the second quarter worth $29,311,000. Finally, State Street Corp lifted its holdings in shares of Protagonist Therapeutics by 18.5% during the second quarter. State Street Corp now owns 3,207,543 shares of the company’s stock worth $177,281,000 after purchasing an additional 500,924 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Performance

Shares of PTGX stock opened at $88.02 on Friday. Protagonist Therapeutics, Inc. has a fifty-two week low of $33.70 and a fifty-two week high of $96.54. The stock has a 50 day simple moving average of $84.24 and a two-hundred day simple moving average of $67.30. The company has a market cap of $5.50 billion, a P/E ratio of 141.96 and a beta of 2.19.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.03). The company had revenue of $4.71 million for the quarter, compared to analyst estimates of $5.41 million. Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%. On average, research analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Insider Buying and Selling

In other Protagonist Therapeutics news, Director William D. Waddill sold 12,000 shares of Protagonist Therapeutics stock in a transaction on Friday, October 10th. The shares were sold at an average price of $81.62, for a total value of $979,440.00. Following the completion of the sale, the director directly owned 5,130 shares of the company’s stock, valued at approximately $418,710.60. The trade was a 70.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.90% of the company’s stock.

Analyst Ratings Changes

PTGX has been the subject of several analyst reports. Johnson Rice set a $112.00 target price on Protagonist Therapeutics in a research report on Monday, October 13th. Barclays increased their price target on Protagonist Therapeutics from $88.00 to $108.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Citigroup lifted their price objective on Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Leerink Partnrs upgraded Protagonist Therapeutics to a “strong-buy” rating in a report on Friday, September 12th. Finally, HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Protagonist Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $85.08.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.